Geron has secured funding deals, and there's strong market potential for its anemia treatment. Read how the biotech is positioning for future growth.

This basic research study presents useful data concerning the menstrual fluid composition and its potential for endometriosis biomarker research. However, despite solid bioinformatics analyses, the ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune ...

IFN-α2 induces sustained major or complete molecular remissions in a subset of PV patients with normalization of the bone marrow after long-term treatment (>60 months). These remissions ...

Researchers detected CD16-positive/MSR1-positive/CEACAM1-positive cells in the bone marrow of a patient with primary MF. The bone marrow of patients with primary ...

On two of these stocks, the analysts have upgraded their stance – a clear sign for investors that these shares deserve a closer look. The Bank of America choices come from widely different areas ...

Giant cell tumor of bone (GCTB) is a rare primary osteolytic bone tumor with high local recurrence rate after surgical resection. Here the authors conduct a phase Ib/II trial, evaluating the ...

SmolLM2 builds on the success of its predecessor, SmolLM1, by offering enhanced capabilities while remaining lightweight. These models come in three configurations: 0.1B, 0.3B, and 1.7B parameters.